BRAF and colonic neoplasm: To test whether these mutations confer resistance to treatment, the effects of unacylated ghrelin were examined in BRAFV600E-transfected MCF7 cells or colon cancer cells (RKO, HCT116) that carry mutations in BRAF or KRAS, respectively.